Form 4 for CTMX CytomX Therapeutics, Inc.
Accepted 2023-09-22 00:00:00 ET · period of report 2023-09-20 · accession 0001610717-23-000299 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-22 | 2023-09-22 | CTMX | BELVIN MARCIA | SVP, CSO | S - Sale | $1.30 | -4,119 | 148.0K | -3% | -$5,355 | |
| 2023-09-22 | 2023-09-20 | CTMX | BELVIN MARCIA | SVP, CSO | A - Grant | $0.00 | +11.2K | 152.1K | +8% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-22 | S | D | 4,119 | $1.30 | 147,951 | D | — | — | (F2) Includes 116,875 restricted stock units. |
| 2 | Common | Common Stock | 2023-09-20 | A | A | 11,250 | $0.00 | 152,070 | D | — | — | (F2) Includes 116,875 restricted stock units. |